{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:34:47Z","timestamp":1793925287560,"version":"4.8.0"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:p>Substance use disorder is challenging to treat due to its relapsing nature. In the last decade, opioid use disorder has been a threat to public health, being declared an epidemic by the Centers for Disease Control and Prevention. This is a tragic situation, considering there currently are only three effective, yet not ideal, treatments to prevent relapse to opioids. Recent research has shown that hormones that modulate hunger and satiety also can modulate motivated behavior for drugs of abuse. For example, the short-acting analog of glucagon-like peptide-1 (GLP-1), an incretin hormone that regulates homeostatic feeding, has been shown to reduce responding for rewarding stimuli such as food, cocaine, heroin, and nicotine when administered over several days or weeks. This may serve as an effective adjuvant during treatment; however, whether it would be effective when used acutely to bridge a patient between cessation of use and onset of medication for the treatment of an opioid addiction is unknown. Here, we tested the acute effects of the longer acting GLP-1 analog, liraglutide, on heroin-seeking. In rats with heroin self-administration experience, we found that subcutaneous administration of an acute dose of 0.3-mg\/kg liraglutide was effective in preventing drug-seeking after exposure to three major precipitators: drug-associated cues, stress (yohimbine-induced), and the drug itself. Finally, we confirmed that the reduction in drug-seeking is not due to a locomotor impairment, as liraglutide did not significantly alter performance in a rotarod test. As such, acute use of GLP-1 analogs may serve as a new and effective nonopioid bridge to treatment.<\/jats:p>","DOI":"10.1097\/fbp.0000000000000685","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T13:09:47Z","timestamp":1655125787000},"page":"364-378","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":39,"title":["Acute glucagon-like peptide-1 receptor agonist liraglutide prevents cue-, stress-, and drug-induced heroin-seeking in rats"],"prefix":"10.1097","volume":"33","author":[{"given":"Joaquin E.","family":"Douton","sequence":"first","affiliation":[{"name":"Department of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil K.","family":"Acharya","sequence":"additional","affiliation":[{"name":"Department of Neural and Behavioral Sciences, Penn State College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Stoltzfus","sequence":"additional","affiliation":[{"name":"Department of Neural and Behavioral Sciences, Penn State College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxiao","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Penn State College of Medicine, Hershey, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia S.","family":"Grigson","sequence":"additional","affiliation":[{"name":"Department of Neural and Behavioral Sciences, Penn State College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Nyland","sequence":"additional","affiliation":[{"name":"Department of Neural and Behavioral Sciences, Penn State College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"102121","DOI":"10.1016\/j.ajp.2020.102121","article-title":"Sublingual buprenorphine-naloxone precipitated withdrawal-a review case report with of literature and clinical considerations.","volume":"53","author":"Bhatia","year":"2020","journal-title":"Asian J Psychiatr"},{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMsa064115","article-title":"Release from prison\u2013a high risk of death for former inmates.","volume":"356","author":"Binswanger","year":"2007","journal-title":"N Engl J Med"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"19168","DOI":"10.1073\/pnas.0507480102","article-title":"Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior.","volume":"102","author":"Boutrel","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R5-20250614","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/(SICI)1098-2396(199605)23:1<28::AID-SYN4>3.0.CO;2-J","article-title":"Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies.","volume":"23","author":"Bremner","year":"1996","journal-title":"Synapse"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/(SICI)1098-2396(199605)23:1<39::AID-SYN5>3.0.CO;2-I","article-title":"Noradrenergic mechanisms in stress and anxiety: II. Clinical studies.","volume":"23","author":"Bremner","year":"1996","journal-title":"Synapse"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"key":"R8-20250614","first-page":"Unit 8.12","article-title":"Motor coordination and balance in rodents.","volume":"Chapter 8","author":"Carter","year":"2001","journal-title":"Curr Protoc Neurosci"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/adb.12164","article-title":"Effect of yohimbine on reinstatement of operant responding in rats is dependent on cue contingency but not food reward history.","volume":"20","author":"Chen","year":"2015","journal-title":"Addict Biol"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2337\/diabetes.53.5.1187","article-title":"One week\u2019s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.","volume":"53","author":"Degn","year":"2004","journal-title":"Diabetes"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1523\/JNEUROSCI.6326-11.2012","article-title":"The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors.","volume":"32","author":"Dickson","year":"2012","journal-title":"J Neurosci"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/FBP.0000000000000609","article-title":"Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin-seeking behavior in rats.","volume":"32","author":"Douton","year":"2021","journal-title":"Behav Pharmacol"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"e13117","DOI":"10.1111\/adb.13117","article-title":"Glucagon-like peptide-1 receptor agonist, liraglutide, reduces heroin self-administration and drug-induced reinstatement of heroin-seeking behaviour in rats.","volume":"27","author":"Douton","year":"2022","journal-title":"Addict Biol"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"113279","DOI":"10.1016\/j.physbeh.2020.113279","article-title":"Effects of a glucagon-like peptide-1 analog on appetitive and consummatory behavior for rewarding and aversive gustatory stimuli in rats.","volume":"229","author":"Douton","year":"2021","journal-title":"Physiol Behav"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/jps.3030460322","article-title":"A note on a simple apparatus for detecting neurological deficit in rats and mice.","volume":"46","author":"Dunham","year":"1975","journal-title":"J Pharm Sci"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"e77284","DOI":"10.1371\/journal.pone.0077284","article-title":"The glucagon-like peptide 1 analogue exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice.","volume":"8","author":"Egecioglu","year":"2013","journal-title":"PLoS One"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"e69010","DOI":"10.1371\/journal.pone.0069010","article-title":"The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice.","volume":"8","author":"Egecioglu","year":"2013","journal-title":"PLoS One"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.drugalcdep.2011.09.001","article-title":"Nicotine self-administration and reinstatement of nicotine-seeking in male and female rats.","volume":"121","author":"Feltenstein","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbr.2006.06.039","article-title":"Potentiation of cue-induced reinstatement of cocaine-seeking in rats by the anxiogenic drug yohimbine.","volume":"174","author":"Feltenstein","year":"2006","journal-title":"Behav Brain Res"},{"issue":"Suppl 4","key":"R21-20250614","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1086\/508180","article-title":"Opioid dependence: rationale for and efficacy of existing and new treatments.","volume":"43","author":"Fiellin","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/mp.2012.141","article-title":"GLP-1 analog attenuates cocaine reward.","volume":"18","author":"Graham","year":"2013","journal-title":"Mol Psychiatry"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00213-012-2868-9","article-title":"Yohimbine increases opioid-seeking behavior in heroin-dependent, buprenorphine-maintained individuals.","volume":"225","author":"Greenwald","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1037\/0735-7044.116.2.321","article-title":"Cocaine-induced suppression of saccharin intake: a model of drug-induced devaluation of natural rewards.","volume":"116","author":"Grigson","year":"2002","journal-title":"Behav Neurosci"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/s41386-018-0010-3","article-title":"Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats.","volume":"43","author":"Hernandez","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/adb.12583","article-title":"Activation of glucagon-like peptide-1 receptors in the nucleus accumbens attenuates cocaine seeking in rats.","volume":"24","author":"Hernandez","year":"2019","journal-title":"Addict Biol"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejphar.2006.06.060","article-title":"Influence of pharmacologically-induced experimental anxiety on nociception and antinociception in rats.","volume":"547","author":"Jim\u00e9nez-Vel\u00e1zquez","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0376-8716(03)00060-7","article-title":"Buprenorphine: how to use it right.","volume":"70","author":"Johnson","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/jcph.443","article-title":"Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol\/levonorgestrel.","volume":"55","author":"Kapitza","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"R30-20250614","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1021\/jm9909645","article-title":"Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration.","volume":"43","author":"Knudsen","year":"2000","journal-title":"J Med Chem"},{"key":"R31-20250614","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/add.12208","article-title":"Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.","volume":"108","author":"Krupitsky","year":"2013","journal-title":"Addiction"},{"key":"R32-20250614","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s00213-004-2036-y","article-title":"Role of alpha-2 adrenoceptors in stress-induced reinstatement of alcohol seeking and alcohol self-administration in rats.","volume":"179","author":"L\u00ea","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"R33-20250614","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/sj.npp.1300435","article-title":"Methadone maintenance reduces heroin- and cocaine-induced relapse without affecting stress-induced relapse in a rodent model of poly-drug use.","volume":"29","author":"Leri","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"R34-20250614","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1525-1381.1999.09218.x","article-title":"Drugs of abuse and the brain.","volume":"111","author":"Leshner","year":"1999","journal-title":"Proc Assoc Am Physicians"},{"key":"R35-20250614","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.molmet.2018.11.005","article-title":"GLP-1 modulates the supramammillary nucleus-lateral hypothalamic neurocircuit to control ingestive and motivated behavior in a sex divergent manner.","volume":"20","author":"L\u00f3pez-Ferreras","year":"2019","journal-title":"Mol Metab"},{"key":"R36-20250614","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nrendo.2009.48","article-title":"Incretin-based therapies for type 2 diabetes mellitus.","volume":"5","author":"Lovshin","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"R37-20250614","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1021\/jm070861j","article-title":"Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness.","volume":"50","author":"Madsen","year":"2007","journal-title":"J Med Chem"},{"key":"R38-20250614","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/BF00166947","article-title":"Morphine-induced hyperactivity in rats\u2013a rebound effect?","volume":"347","author":"Magnus-Ellenbroek","year":"1993","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R39-20250614","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ddr.1195","article-title":"Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1.","volume":"53","author":"Parkes","year":"2001","journal-title":"Drug Dev Res"},{"key":"R40-20250614","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pbb.2013.04.010","article-title":"A novel model of chronic sleep restriction reveals an increase in the perceived incentive reward value of cocaine in high drug-taking rats.","volume":"109","author":"Puhl","year":"2013","journal-title":"Pharmacol Biochem Behav"},{"key":"R41-20250614","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.molmet.2015.05.005","article-title":"Glucose intolerance induced by blockade of central FGF receptors is linked to an acute stress response.","volume":"4","author":"Rojas","year":"2015","journal-title":"Mol Metab"},{"key":"R42-20250614","doi-asserted-by":"crossref","first-page":"654","DOI":"10.2337\/db18-0498","article-title":"Peripheral mechanisms mediating the sustained antidiabetic action of FGF1 in the brain.","volume":"68","author":"Scarlett","year":"2019","journal-title":"Diabetes"},{"key":"R43-20250614","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.","volume":"124","author":"Secher","year":"2014","journal-title":"J Clin Invest"},{"key":"R44-20250614","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1523\/JNEUROSCI.17-07-02605.1997","article-title":"Corticotropin-releasing factor, but not corticosterone, is involved in stress-induced relapse to heroin-seeking in rats.","volume":"17","author":"Shaham","year":"1997","journal-title":"J Neurosci"},{"key":"R45-20250614","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.biopsych.2004.02.032","article-title":"The anxiogenic drug yohimbine reinstates methamphetamine seeking in a rat model of drug relapse.","volume":"55","author":"Shepard","year":"2004","journal-title":"Biol Psychiatry"},{"key":"R46-20250614","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/HCR.0000000000000112","article-title":"Treatment of obesity in 2015.","volume":"35","author":"Shukla","year":"2015","journal-title":"J Cardiopulm Rehabil Prev"},{"key":"R47-20250614","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.physbeh.2015.06.013","article-title":"The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice.","volume":"149","author":"S\u00f8rensen","year":"2015","journal-title":"Physiol Behav"},{"key":"R48-20250614","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/sj.npp.1300712","article-title":"Rats maintained chronically on buprenorphine show reduced heroin and cocaine seeking in tests of extinction and drug-induced reinstatement.","volume":"30","author":"Sorge","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"R49-20250614","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1098\/rstb.2008.0084","article-title":"Review. Psychological and neural mechanisms of relapse.","volume":"363","author":"Stewart","year":"2008","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"R50-20250614","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.pbb.2017.07.014","article-title":"The glucagon-like peptide 1 receptor agonist Exendin-4 decreases relapse-like drinking in socially housed mice.","volume":"160","author":"Thomsen","year":"2017","journal-title":"Pharmacol Biochem Behav"},{"key":"R51-20250614","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neulet.2015.09.008","article-title":"Yohimbine is a 5-HT1A agonist in rats in doses exceeding 1\u2009mg\/kg.","volume":"606","author":"Zaretsky","year":"2015","journal-title":"Neurosci Lett"},{"key":"R52-20250614","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41386-019-0531-4","article-title":"Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats.","volume":"45","author":"Zhang","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"R53-20250614","doi-asserted-by":"crossref","first-page":"108599","DOI":"10.1016\/j.neuropharm.2021.108599","article-title":"A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats.","volume":"192","author":"Zhang","year":"2021","journal-title":"Neuropharmacology"}],"container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000685","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T22:02:42Z","timestamp":1749938562000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/fbp.0000000000000685","relation":{},"ISSN":["0955-8810"],"issn-type":[{"value":"0955-8810","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,7]]}}}